Heart Failure – Landscape & Forecast – Disease Landscape & Forecast
Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this progress relates mainly to chronic HF (CHF), particularly HF with reduced ejection fraction (HFrEF). Substantial unmet need remains in the treatment of HF with preserved ejection fraction (HFpEF). This report provides insight into the current and future CHF and acute HF (AHF) markets, as well as the expected dynamics of the HFrEF and HFpEF markets following the market entries of several new therapies (Boehringer Ingelheim / Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, and Bayer / MSD’s vericiguat). This report also assesses how the AHF market will evolve given the lack of new drug launches for this patient population
QUESTIONS ANSWERED
- How large are the treatable AHF, HFrEF, and HFpEF populations, and how will diagnosis rates change over time?
- What is the state of treatment for heart failure? What are the most important drugs and why? Which clinical needs remain unfulfilled?
- How will the use of Entresto evolve over the forecast period?
- How will the treatment of HFpEF change following the launches of the first evidence-based drugs for this population?
- For which emerging therapies do thought leaders express the most enthusiasm, and what level of market penetration can they expect?
GEOGRAPHIES
United States, EU5, Japan.
PRIMARY RESEARCH
20 country-specific interviews with thought-leading cardiologists; supported by survey data collected for this and other Clarivate research.
EPIDEMIOLOGY
Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction.
FORECAST
10-year, annualized, drug-level sales and patient shares of key HF therapies through 2032, segmented by brands / generics and ejection fraction (HFrEF and HFpEF).
EMERGING THERAPIES
Phase 3/PR: 4 drugs; Phase 2: 8 drugs.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Heart Failure - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for heart failure?
- What factors are constraining the market for heart failure?
- Patient share of AHF drug classes in the major pharmaceutical markets: 2022-2032
- Patient share of HFrEF drug classes in the major pharmaceutical markets: 2022-2032
- Patient share of HFpEF drug classes in the major pharmaceutical markets: 2022-2032
- Drug-class-specific trends
- Loop diuretics
- Inotropic sympathomimetics, phosphodiesterase 3 inhibitors, and calcium sensitizers
- Natriuretic peptide receptor agonists
- ACE inhibitors and ARBs
- Angiotensin receptor-neprilysin inhibitors
- HCN channel blockers
- Mineralocorticoid receptor antagonists
- SGLT-2 inhibitors
- Soluble guanylate cyclase stimulators
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Key findings
- Epidemiology populations
- Diagnosed events of acute heart failure
- Diagnosed prevalent cases of chronic heart failure
- Diagnosed prevalent cases of chronic heart failure by NYHA functional classification scheme
- Diagnosed prevalent cases of chronic heart failure by ejection fraction
- Drug-treated prevalent cases of CHF and events of AHF
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for acute and chronic heart failure
- Current treatments used for acute heart failure
- Current treatments used for chronic heart failure
- Loop diuretics
- Nitrate vasodilators
- Inotropic sympathomimetics
- Phosphodiesterase 3 inhibitors
- Natriuretic peptide receptor agonists
- Calcium sensitizers
- ACE inhibitors
- Angiotensin II receptor blockers
- ARNIs
- Beta blockers
- Mineralocorticoid receptor antagonists
- Digitalis glycosides
- HCN channel blockers
- Vasodilator combination therapies
- Vasopressin receptor antagonists
- SGLT-2 inhibitors
- Soluble guanylate cyclase stimulator
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Notable developments among key emerging therapies for heart failure
- Key therapies in development for heart failure
- Estimated launch dates of key emerging therapies for the treatment of heart failure
- GIP / GLP-1 receptor agonists
- SGLT-2 inhibitors
- Mineralocorticoid receptor antagonists
- Stem cell therapies
- Interleukin-6 inhibitor
- GLP-1 receptor agonists
- Early-phase pipeline analysis
- Key discontinuations and failures in heart failure
- Key findings
- Access & Reimbursement Overview
- Methodology
- Appendix
Dwaipayan Chatterjee, M.Pharm., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders analyst. Mr. Chatterjee authors reports on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.